Login / Signup

Cardiovascular Outcomes in Patients Initiating First-Line Treatment of Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors Versus Metformin.

HoJin ShinSebastian G SchneeweissRobert J GlynnElisabetta Patorno
Published in: Annals of internal medicine (2022)
Keyphrases
  • type diabetes
  • end stage renal disease
  • ejection fraction
  • chronic kidney disease
  • newly diagnosed
  • prognostic factors
  • cardiovascular disease
  • metabolic syndrome
  • patient reported outcomes